Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Restructure Sees Drug Development And Oncology Chiefs Exit

Aims To Boost R&D And Commercial Performance

Executive Summary

Tsai and Schaffert out as the Swiss giant looks to maximize returns from its US business, and find more transformational drugs with the help of a new ‘strategy and growth officer’.

You may also be interested in...



Novartis Boosts Biologics Offering With $300m Investment In European Facilities

The funds will help advance biologic R&D, manufacturing and commercialization capabilities across Europe as the major pursues more sophisticated modalities, its global biologics head tells Scrip.

Sandoz Says All Options Still Open After Spinoff Rumors

Sandoz has responded to recent rumors that parent company Novartis is favoring a spinoff of the generics and biosimilars business over a sale or retention, insisting that “all options remain open” as a strategic review of the unit continues.

Novartis To Cut 8,000 Jobs In Global Restructure

CEO Vas Narasimhan wants the company to be more agile and identify more blockbuster opportunities.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146169

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel